

Invitrocue launches world's first commercial Personalised Cancer Screening Service : Onco-PDO™

April 13, 2018 – Invitrocue (ASX:IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce that it has screened the first commercial Onco-PDO™ customer in Singapore for the indication of Colorectal Cancer.

Invitrocue's Onco-PDO™ test provides an overview of how a patient's cancer cells respond to different standard of care chemotherapies, ranking these therapeutics based on their effectiveness in delivering a positive response. This approach allows oncologists to develop better informed and more personalised treatment strategies for patients.

Screening the PDO models for therapeutic sensitivity for the first paying customer signals the initial commercial applications of its technology and approach in the Asia Pacific region. Invitrocue has identified key medical channel partners for Singapore in consultation with their oncologists, and will also be receiving patients from Hong Kong who are looking to utilise the Onco-PDO™ platform.

All clinical work to offer Onco-PDO™ services is being carried out at the joint laboratory established last year between the Genome Institute of Singapore (GIS) and Invitrocue, which is located at A*STAR, the Singapore government's Agency for Science, Technology and Research.

Invitrocue CEO, Dr Steven Fang commented:

"We are incredibly excited to have screened our first patient in Singapore against the Onco-PDO™ drug sensitivity test, and are encouraged by the response and interest so far from both local and international oncologists in using this technology with their patients to better inform their decision making process when dealing with a variety of cancer types. We look forward to updating the market on our progress as we continue to commercialise our platform both in Singapore and globally".

- ENDS -

For more information, please contact:

Martin D. Bach, VP Operations

T: +65 6460 0490

martind.bach@invitrocue.com

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions including *in vitro* cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine). Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

About A*STAR

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities. For more information visit (www.a-star.edu.sg).

About the Genome Institute of Singapore (GIS)

The Genome Institute of Singapore (GIS) is a national, government supported initiative which falls under A*STAR and seeks to use genomic sciences to achieve significant improvements in human health. As one of the world's leading centers for genomic discovery, the GIS pursues the integration of technology, genetics and biology towards the goal of individualized medicine. For more information visit ([www. https://www.a-star.edu.sg/gis/](https://www.a-star.edu.sg/gis/)).

For personal use only